IDM Pharma Completes Sale of Non-Core Assets to Pharmexa A/S for $12 Million Cash
In connection with the asset sale, IDM and Pharmexa entered into fully paid up perpetual license agreements, which guarantee IDM continuing rights to use the PADRE(R) and Epitope Identification System (EIS(R)) technologies in the cancer field, and a three-year services agreement which assures IDM of certain services required for its ongoing clinical trials as well as access to expertise and know-how related to epitope identification. IDM retains all rights related to its cancer programs.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.